JP2008542309A - ペプチドベースのインフルエンザワクチン製剤 - Google Patents
ペプチドベースのインフルエンザワクチン製剤 Download PDFInfo
- Publication number
- JP2008542309A JP2008542309A JP2008513881A JP2008513881A JP2008542309A JP 2008542309 A JP2008542309 A JP 2008542309A JP 2008513881 A JP2008513881 A JP 2008513881A JP 2008513881 A JP2008513881 A JP 2008513881A JP 2008542309 A JP2008542309 A JP 2008542309A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- influenza
- vaccine
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 97
- 239000000203 mixture Substances 0.000 title claims abstract description 91
- 238000009472 formulation Methods 0.000 title claims abstract description 84
- 229960003971 influenza vaccine Drugs 0.000 title description 22
- 229960005486 vaccine Drugs 0.000 claims abstract description 85
- 206010022000 influenza Diseases 0.000 claims abstract description 64
- 238000004519 manufacturing process Methods 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 27
- 241000283073 Equus caballus Species 0.000 claims description 20
- 239000002671 adjuvant Substances 0.000 claims description 15
- 241000282414 Homo sapiens Species 0.000 claims description 12
- 229940037003 alum Drugs 0.000 claims description 12
- 208000002979 Influenza in Birds Diseases 0.000 claims description 10
- 206010064097 avian influenza Diseases 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 abstract description 27
- 208000037797 influenza A Diseases 0.000 abstract description 8
- 208000037798 influenza B Diseases 0.000 abstract description 5
- 241000283086 Equidae Species 0.000 abstract description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 23
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 23
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 23
- 101710176177 Protein A56 Proteins 0.000 description 23
- 239000000185 hemagglutinin Substances 0.000 description 20
- 230000035931 haemagglutination Effects 0.000 description 15
- 238000004949 mass spectrometry Methods 0.000 description 15
- 230000000890 antigenic effect Effects 0.000 description 13
- 241000700605 Viruses Species 0.000 description 12
- 241000712461 unidentified influenza virus Species 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000004727 humoral immunity Effects 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 241000271566 Aves Species 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108010006232 Neuraminidase Proteins 0.000 description 3
- 102000005348 Neuraminidase Human genes 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- -1 9-fluorenylmethoxycarbonyl (Fmoc) Chemical class 0.000 description 2
- 241001050985 Disco Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101710180643 Leishmanolysin Proteins 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000004880 explosion Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 101001081183 Homo sapiens Minor histocompatibility protein HB-1 Proteins 0.000 description 1
- 101710141347 Major envelope glycoprotein Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000050542 human HMHB1 Human genes 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 230000008478 viral entry into host cell Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
【選択図】 なし
Description
本願は、2005年6月1日に出願された米国仮特許出願第60/686,041号の優先権の利益を主張し、この仮特許出願は参照により本明細書に組み入れられる。
本発明は、概して抗ウイルス製剤に関し、特にペプチドベースのインフルエンザワクチン製剤に関する。
インフルエンザは、オルトミクソウイルス科のウイルスに関連する呼吸器系の一般的な感染性疾患である。このウイルスは変異性が高いので、ワクチン接種は通例、株変異を考慮に入れた処方変更済のワクチンを使って、毎年行う必要がある。そのような処方変更にもかかわらず、ある特定シーズン中に世界中の人々に活発に感染するさまざまな株の全てを包含することは、ワクチンには不可能である。
従来のインフルエンザワクチン製剤の少なくとも一つの欠点を除去又は軽減することが、本発明の目的である。
本発明は、概して抗ウイルス製剤を提供し、より具体的には、配列番号1〜248からなる群より選択される少なくとも1個のペプチドを含むペプチドベースの抗インフルエンザ製剤を提供する。
本発明のワクチン製剤では、インフルエンザ赤血球凝集素を使って、四つの不連続エピトープを表現する直鎖配列を設計する。HAの四つの抗原部位にある不連続B細胞エピトープ及び不連続T細胞エピトープを模倣する四つのペプチド(discotopeコンストラクト)を設計した。各discotopeコンストラクトは、固相ペプチド合成法を使って合成される。インフルエンザA型の200株を越えるヒト分離株の配列を、Genbank(商標)データベース及びSwiss Protein(商標)データベースから入手し、これらのエピトープの組成を調べるために整列した。
本発明の文脈において、ワクチン製剤は、インフルエンザワクチンの製造に用いられるペプチドのカクテルである。このワクチンは、ペプチドのカクテルと、添加が許容されるであろう当分野において既知の他の置換成分とを含むことができる。これらの置換成分としては、アジュバント、希釈剤及び/又は担体を挙げることができるが、これらに限定されるわけではない。
標準的な固相ペプチド化学を使ってペプチドを合成した。ペプチドは、9−フルオレニルメトキシカルボニル(Fmoc)化学を用いる固相ペプチド合成法(SPPS)により、Pioneer(商標)自動ペプチド合成装置で、担持済(pre−loaded)Fmoc保護NovaSyn(商標)TGT樹脂(NovaBiochem)を記述されているとおりに使用して合成した。与えられた位置で変異性が望まれる場合は、その位置に2つのアミノ酸の混合物を入れる。合成の間、変異性が望まれる位置ではいつでも、この操作を繰り返す。アミノ酸のカップリングには2−(1H−ベンゾトリアゾール−1−イル)−1,1,3,3−テトラメチルウロニウムテトラフルオロボレート(TBTU)及びN−ヒドロキシベンゾトリアゾール(HOBt)の1Mジメチルホルムアミド(DMF)溶液、並びにジイソプロピルエチルアミン(DIPEA)の1M DMF溶液を使用し、合成中のアミノ酸の脱保護には20%ピペリジン/DMFを使用した。
本実施例では、B6マウスを、INF−01Pワクチン+ミョウバン、Ribi若しくはMontanide、又は市販のワクチン(2004〜2005シーズン)で免疫処置した。ウイルスへの曝露の前日に、ワクチン接種したマウスから血清を得た。マウスを病原性A/HK/1/68−MA20cウイルスに曝露し、曝露後3週間にわたって追跡した。
B6マウスをINFE−01P(ウマインフルエンザ)ワクチン+ミョウバンで免疫処置するか、市販のワクチン(2004〜2005シーズン)で免疫処置した。そのマウスから得た血清を、いくつかのインフルエンザ株(H3N2 A/Hong Kong/1/68g、H1N1 A/FM/1/47、H5N1 A/Hong Kong/213/2003、B/Mass/3/66、及びH1N1 A/New Caledonia/20/1999)に対するHAI活性について試験した。血清は最初のワクチン接種後に得た。
赤血球凝集(HAI)アッセイ
個々のdiscotopeコンストラクト及び組み合わされたdiscotopeコンストラクトの免疫原性をマウスで評価した。四つのdiscotopeコンストラクトで免疫処置したマウスは、全体として、ウイルスの赤血球凝集活性を抑制することができる抗体を発生させた。インフルエンザに基づくdiscotopeコンストラクトは、インフルエンザウイルスによる赤血球の血球凝集反応を抑制する抗体が誘発されたという点で、不連続エピトープをうまく模倣することが示された。
Claims (28)
- 配列番号1〜248からなる群より選択される少なくとも1個のペプチドを含むペプチドベースの抗インフルエンザ製剤。
- 配列番号1〜248からなる群より選択される少なくとも4個のペプチド配列を含む、請求項1に記載の製剤。
- 配列番号1〜64からなる群より選択される少なくとも2個のペプチドと、配列番号133〜180からなる群より選択される少なくとも2個のペプチドとを含む、請求項1に記載の製剤。
- 配列番号1〜64及び配列番号133〜180を含む、請求項3に記載の製剤。
- 請求項185〜248からなる群より選択される少なくとも1個のペプチド配列を含む、請求項1に記載の製剤。
- 配列番号65〜128からなる群より選択される少なくとも1個のペプチド配列を含む、請求項1に記載の製剤。
- 以下に挙げる群のうち少なくとも2つの群のそれぞれから選択される2n個のペプチド配列を含む、請求項1に記載の製剤。
a)配列番号1〜16;
b)配列番号17〜32;
c)配列番号33〜48;及び
d)配列番号49〜64
[ただし、nは1〜4である。] - 以下に挙げる群a)〜d)のうち少なくとも2つの群を含む、請求項1に記載の製剤。
a)配列番号133〜140から選択される2m個のペプチド配列;
b)配列番号141〜156から選択される2n個のペプチド配列;
c)配列番号157〜172から選択される2n個のペプチド配列;及び
d)配列番号173〜180から選択される2m個のペプチド配列
[ただし、mは1〜3であり、nは1〜4である。] - 以下に挙げる群のうち少なくとも2つの群のそれぞれから選択される2n個のペプチド配列を含む、請求項1に記載の製剤。
a)配列番号185〜200;
b)配列番号201〜216;
c)配列番号217〜232;及び
d)配列番号233〜248
[ただし、nは1〜4である。] - 以下に挙げる群のうち少なくとも2つの群のそれぞれから選択される2n個のペプチド配列を含む、請求項1に記載の製剤。
a)配列番号65〜80;
b)配列番号81〜96;
c)配列番号97〜112;及び
d)配列番号113〜128
[ただし、nは1〜4である。] - 配列番号129〜132又は配列番号181〜184の少なくとも一方を含む、請求項1に記載の製剤。
- 配列番号129〜132を含む、請求項11に記載の製剤。
- 配列番号181〜184を含む、請求項11に記載の製剤。
- 配列番号1〜64を含む、請求項1に記載の製剤。
- 配列番号185〜248を含む、請求項1に記載の製剤。
- 請求項1に記載の製剤を、薬学的に許容できる希釈剤又は担体と共に含むワクチン。
- 更にアジュバントを含む、請求項16に記載のワクチン。
- 前記アジュバントがミョウバンである、請求項17に記載のワクチン。
- インフルエンザを予防又は治療する必要がある動物におけるインフルエンザを予防又は治療するためのワクチンの製造のための、請求項1に記載の製剤の使用。
- 前記動物がヒト、マウス、ウマ又はトリである、請求項19に記載の使用。
- ヒトインフルエンザを治療するためのワクチンの製造のための、請求項3に記載の製剤の使用。
- ウマインフルエンザを治療するためのワクチンの製造のための、請求項5に記載の製剤の使用。
- トリインフルエンザを治療するためのワクチンの製造のための、請求項6に記載の製剤の使用。
- インフルエンザの予防又は治療のための、請求項16に記載のワクチンの使用。
- 請求項3に記載の製剤を含むワクチン。
- 更にアジュバントを含む、請求項25に記載のワクチン。
- 前記アジュバントがミョウバンである、請求項26に記載のワクチン。
- インフルエンザを予防又は治療する必要がある動物におけるインフルエンザを予防又は治療する方法であって、請求項16に記載のワクチンの有効量を当該動物に投与することを含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68604105P | 2005-06-01 | 2005-06-01 | |
US60/686,041 | 2005-06-01 | ||
PCT/CA2006/000891 WO2006128294A1 (en) | 2005-06-01 | 2006-06-01 | Peptide-based influenza vaccine formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008542309A true JP2008542309A (ja) | 2008-11-27 |
JP4939531B2 JP4939531B2 (ja) | 2012-05-30 |
Family
ID=37481185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008513881A Expired - Fee Related JP4939531B2 (ja) | 2005-06-01 | 2006-06-01 | ペプチドベースのインフルエンザワクチン製剤 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20090104216A1 (ja) |
EP (1) | EP1906998A4 (ja) |
JP (1) | JP4939531B2 (ja) |
KR (1) | KR20080027777A (ja) |
CN (1) | CN101227919B (ja) |
CA (1) | CA2610667A1 (ja) |
MX (1) | MX2007015105A (ja) |
WO (1) | WO2006128294A1 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11865172B2 (en) | 2005-04-21 | 2024-01-09 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
US7959929B2 (en) | 2005-04-21 | 2011-06-14 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
WO2007120834A2 (en) * | 2006-04-13 | 2007-10-25 | Peptimmune, Inc. | Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability |
US20090036653A1 (en) * | 2006-04-13 | 2009-02-05 | Peptimmune, Inc. | Methods for the directed expansion of epitopes for use as antibody ligands |
US20100068224A1 (en) * | 2006-04-24 | 2010-03-18 | Roberto Crea | Method for Producing Viral Vaccine and Therapeutic Peptide Antigens |
WO2009053535A2 (en) * | 2007-10-26 | 2009-04-30 | Glykos Finland Oy | Peptide vaccine for influenza virus |
FI20060946A0 (fi) * | 2006-10-26 | 2006-10-26 | Glykos Finland Oy | Influenssaviruksen nukleiinihappoja ja peptidejä |
EP2097103B1 (en) * | 2006-11-30 | 2012-10-03 | Variation Biotechnologies Inc. | Influenza vaccine formulation |
BRPI0811293A2 (pt) * | 2007-05-07 | 2017-05-16 | Peptimmune Inc | métodos para a expansão direta de epítopos para uso com ligantes de anticorpo. |
GB0714963D0 (en) * | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
PL2173376T3 (pl) | 2007-08-02 | 2015-08-31 | Biondvax Pharmaceuticals Ltd | Multimeryczne wieloepitopowe szczepionki przeciwko grypie |
BRPI0817682A2 (pt) * | 2007-10-16 | 2015-04-07 | Peptimmune Inc | Métodos para projetar e preparar vacinas compreendendo composições de polímero de sequência direcionada via a expansão direta de epítopos |
CA2759118A1 (en) * | 2008-04-17 | 2009-10-22 | Declion Pharmaceuticals, Inc. | Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders |
FI20080333A0 (fi) * | 2008-05-02 | 2008-05-02 | Glykos Finland Oy | Influenssaviruksen nukleiinihappoja ja peptidejä |
CA2735724C (en) * | 2008-06-19 | 2018-07-24 | Variation Biotechnologies Inc. | Compositions and methods for treating influenza |
EP2646459B1 (en) | 2010-12-02 | 2020-01-08 | Bionor Immuno AS | Peptide scaffold design |
WO2012114323A1 (en) | 2011-02-22 | 2012-08-30 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |
MY184269A (en) | 2015-11-27 | 2021-03-30 | Viramatix Sdn Bhd | Broad-spectrum anti-influenza virus therapeutic peptides |
KR20200012894A (ko) | 2017-05-26 | 2020-02-05 | 비라매틱스 에스디엔 비에이치디 | 펩타이드 및 항바이러스제로서의 이의 용도 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05262667A (ja) * | 1991-12-11 | 1993-10-12 | American Home Prod Corp | ウイルス抗原を用いるワクチン |
WO2003066090A1 (en) * | 2002-02-08 | 2003-08-14 | Variation Biotechnologies Inc. | Immunogenic formulations of variable peptidic epitopes and process for preparation thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7118874B2 (en) * | 1998-10-09 | 2006-10-10 | Variation Biotechnologies Inc. | Immunogenic formulation and process for preparation thereof |
IL127331A0 (en) * | 1998-11-30 | 1999-09-22 | Yeda Res & Dev | Peptide-based vaccine for influenza |
US20040223976A1 (en) * | 2003-03-07 | 2004-11-11 | Elisabetta Bianchi | Influenza virus vaccine |
-
2006
- 2006-06-01 CA CA002610667A patent/CA2610667A1/en not_active Abandoned
- 2006-06-01 US US11/921,436 patent/US20090104216A1/en not_active Abandoned
- 2006-06-01 KR KR1020077029582A patent/KR20080027777A/ko not_active Application Discontinuation
- 2006-06-01 WO PCT/CA2006/000891 patent/WO2006128294A1/en active Application Filing
- 2006-06-01 JP JP2008513881A patent/JP4939531B2/ja not_active Expired - Fee Related
- 2006-06-01 EP EP06741591A patent/EP1906998A4/en not_active Withdrawn
- 2006-06-01 CN CN200680023950XA patent/CN101227919B/zh not_active Expired - Fee Related
- 2006-06-01 MX MX2007015105A patent/MX2007015105A/es not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05262667A (ja) * | 1991-12-11 | 1993-10-12 | American Home Prod Corp | ウイルス抗原を用いるワクチン |
WO2003066090A1 (en) * | 2002-02-08 | 2003-08-14 | Variation Biotechnologies Inc. | Immunogenic formulations of variable peptidic epitopes and process for preparation thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1906998A1 (en) | 2008-04-09 |
EP1906998A4 (en) | 2010-02-17 |
CN101227919B (zh) | 2011-10-05 |
WO2006128294A1 (en) | 2006-12-07 |
KR20080027777A (ko) | 2008-03-28 |
JP4939531B2 (ja) | 2012-05-30 |
CN101227919A (zh) | 2008-07-23 |
CA2610667A1 (en) | 2006-12-07 |
US20090104216A1 (en) | 2009-04-23 |
MX2007015105A (es) | 2008-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4939531B2 (ja) | ペプチドベースのインフルエンザワクチン製剤 | |
US20210046176A1 (en) | Methods of generating broadly protective vaccine compositions comprising neuraminidase | |
Heinimäki et al. | Live baculovirus acts as a strong B and T cell adjuvant for monomeric and oligomeric protein antigens | |
Music et al. | Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus-like particles confers improved cross-protection in ferrets | |
US7807173B2 (en) | Influenza vaccine formulation | |
Subbramanian et al. | Age-related changes in magnitude and diversity of cross-reactive CD4+ T-cell responses to the novel pandemic H1N1 influenza hemagglutinin | |
WO2011079817A1 (zh) | Tuftsin和流感基质蛋白的树状聚合物及其应用 | |
US10195266B2 (en) | Versatile influenza virus vaccine composition | |
CN110003314B (zh) | H1n1流感病毒血凝素可诱发广谱保护性抗体的表位肽及其应用 | |
AU2018325899B2 (en) | Method for producing influenza HA split vaccine | |
US20210299241A1 (en) | Reverse peptide vaccine | |
CN113747915A (zh) | 优化的疫苗组合物及其制备方法 | |
Stropkovská et al. | Broadly cross-reactive monoclonal antibodies against HA2 glycopeptide of Influenza A virus hemagglutinin of H3 subtype reduce replication of influenza A viruses of human and avian origin | |
Nagy et al. | The intersubunit region of the influenza virus haemagglutinin is recognized by antibodies during infection | |
US11576964B2 (en) | Methods of generating broadly protective vaccine compositions comprising hemagglutinin | |
Honda-Okubo et al. | Panblok-H1+ advax H1N1/2009pdm vaccine: Insights into rapid development of a delta inulin adjuvanted recombinant pandemic influenza vaccine | |
Gao et al. | A dominant Th epitope in influenza nucleoprotein. Analysis of the fine specificity and functional repertoire of T cells recognizing a single determinant. | |
EP2012829A2 (en) | Method for producing viral vaccine and therapeutic peptide antigens | |
CN115850398B (zh) | 新型冠状病毒奥密克戎系列变异株的多肽组合物及其应用 | |
WO2010146848A1 (en) | An antigenic peptide derived from influenza virus and a method for selecting anti-influenza virus antibody | |
JPH02504284A (ja) | 抗原、および、抗イディオタイプ抗体、または抗原に対する細胞受容体に特異的な抗体に共通のアミノ酸配列に由来する免疫原および生物学的活性ペプチド |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110518 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110614 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110906 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120207 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120224 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150302 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
LAPS | Cancellation because of no payment of annual fees |